Horm Metab Res 2015; 47(07): 504-508
DOI: 10.1055/s-0034-1384587
Endocrine Care
© Georg Thieme Verlag KG Stuttgart · New York

A Double-Blind, Placebo-Controlled Trial Related to the Effects of Melatonin on Oxidative Stress and Inflammatory Parameters of Obese Women

N. Mesri Alamdari
1  Students Research Committee, School of Nutrition, Tabriz University of Medical Science, Tabriz, Iran
,
R. Mahdavi
2  Nutrition Research Center, School of Nutrition, Tabriz University of Medical Science, Tabriz, Iran
,
N. Roshanravan
1  Students Research Committee, School of Nutrition, Tabriz University of Medical Science, Tabriz, Iran
,
N. Lotfi Yaghin
1  Students Research Committee, School of Nutrition, Tabriz University of Medical Science, Tabriz, Iran
,
A. R. Ostadrahimi
2  Nutrition Research Center, School of Nutrition, Tabriz University of Medical Science, Tabriz, Iran
,
E. Faramarzi
3  Common Disease Risk Factors Management Institute, Tabriz University of Medical Sciences, Tabriz, Iran
› Author Affiliations
Further Information

Publication History

received 15 April 2014

accepted 30 June 2014

Publication Date:
15 August 2014 (online)

Abstract

Obesity, the global epidemic health problem, results in chronic disorders. Melatonin supplementation may prevent the adverse health consequences of obesity. The aim of this study was to assess the effects of melatonin supplementation on inflammatory and oxidative stress parameters in obese women. In randomized, double-blind, placebo-controlled trial, 44 obese women were randomly assigned to melatonin (n=22) and placebo (n=22) groups. Subjects were supplemented with a daily dose of 6 mg melatonin or placebo with low calorie diet for 40 days. Serum TNF-α, IL-6, hsCRP, TAC, and MDA levels were assessed before and after intervention. In the melatonin group, mean serum TNF-α, IL-6, hsCRP, and MDA levels decreased significantly (p<0.05) from 3.52±0.72 pg/ml, 27.12±6.32 pg/ml, 2.54±0.49 mg/l, and 3.81±0.29 nmol/l to 1.73±0.07, 16.34±6.32, 1.67±0.27, and 2.79±0.29, respectively. Whilst in the placebo group the decrease in values were not statistically significant. Mean TAC level increased slightly (from 1.11±0.30 to 1.14±0.45 mmol/l) in the melatonin group whereas it decreased slightly (from 1.13±0.15 to 1.08±0.21 nmol/l) in the placebo group. Significant differences were observed only for TNF-α (p=0.02) and IL-6 (p=0.03) between the 2 study groups. Considering the improvements in inflammatory and oxidative stress factors in obese women, it seems that melatonin supplementation may provide beneficial effects in obesity treatment by ameliorating some of its complications. However, further studies are needed to make concise conclusions.